This webinar will be hosted live and available on-demand
Tuesday, March 7, 2023
1:00 PM Eastern Time
The gut microbiome contributes to the host immune activation in health and disease. During cancer development and progression, the gut microbiome shows distinct signatures in patients who responded favorably to immune checkpoint inhibitor therapy (ICT).
In this webinar brought to you by IsoPlexis, Andrew Y. Koh will discuss how scientists used functional proteomics to examine the effect of the gut microbiome on the adaptive immune response, enhancing ICT efficacy in a preclinical melanoma model.
Topics to be Covered
- Gut microbiome comparisons during ICT therapy in clinical studies
- Identifying gut microbiome signatures associated with ICT
- Modeling cancer gut microbiome in a preclinical model
Andrew Y. Koh, MD